- On its way to becoming a fully integrated company, Norland MedicalSystems has gained shareholder approval to proceed with the acquisition of Norland Corp, which manufactures DXA bone densitometers. All outstanding stock will be purchased for $17.5 million, with a possible additional payment of $2.5 million based on performance. An upfront cash payment of $1.25 million will be made, with another $1.25 million payable in March next year, and the remainder payable in full at maturity in five years, in either cash or stock.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze